Status:
COMPLETED
Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-49 years
Phase:
PHASE1
Brief Summary
The study is carried out in order to investigate safety, tolerability and pharmacokinetics after administrating single and fractionated doses of AZD3241 to healthy volunteers
Eligibility Criteria
Inclusion
- Provision of informed consent
- Body Mass Index (BMI) 19 to 30 kg/m2 inclusive
- Clinically normal physical findings, including BP, pulse rate, ECG and laboratory findings, as judged by the investigator
Exclusion
- Clinically significant illness within the 2 weeks prior to the administration of the investigational product
- Heart rate (resting, recumbent) \<50 bmp or \>85 bmp
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity as judged by the investigator
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2008
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00729443
Start Date
July 1 2008
End Date
November 1 2008
Last Update
November 13 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden